Therapy Areas: Vaccines
Vaxxinity Signs Purchase Order with the Government of Paraguay for 1m Doses of Vaxxinity's UB-612 COVID-19 Vaccine
21 June 2021 - - US-based immunotherapeutic vaccines developer Vaxxinity, in close collaboration with UBI-Asia, has inked a purchase order for its COVID-19 vaccine, UB-612, with the government of Paraguay, contingent upon issuance of an Emergency Use Authorization by the Taiwanese Food and Drug Administration, which will trigger an EUA in Paraguay, the company said.

The order was signed on June 16 in Asunción by Dr. Julio Borba, Paraguay Minister of Health and Social Welfare, and Jon Harrison, Vaxxinity Chief Strategy officer. Ambassador José Han, Taiwan's Ambassador to Paraguay, was also present (pictured).

The UB-612 vaccine is expected to be delivered later this summer, pending issuance of an EUA by the TFDA and subsequent registration by Paraguay's National Health Surveillance Authority (DINAVISA). 

As the Ministry of Health and Welfare noted a leadership shown on June 16 by the government of Paraguay guarantees that Paraguay will be one of the first countries in the world to receive UB-612 once it is issued an EUA.

Vaxxinity, in close collaboration with its partner, UBI-Asia, is completing a large Phase 2 clinical trial of UB-612 in Taiwan, with support from Taiwan's Ministry of Health and Welfare, and will soon begin its Phase 2/3 efficacy trial in India in partnership with Aurobindo.

Vaxxinity has also announced a global logistics partnership with Maersk, the world's largest shipping and integrated logistics provider, that creates a framework for all transportation and supply chain services that will be needed to deliver UB-612 around the world.

The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.

Headquartered in Dallas, TX, with partners in the United States, Latin America, Europe, and Asia, Vaxxinity's proprietary Multitope technology platform has enabled the innovation of synthetic peptide vaccines designed to treat and prevent infectious diseases, including COVID-19, and chronic diseases, such as Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.

Unlike vaccines designed to prevent exogenous diseases, Vaxxinity's chronic disease pipeline is designed to train the body to produce its own antibodies against internal targets of disease.

This comes with practical administrative and cost advantages versus monoclonal antibodies, meaning that Vaxxinity may, if approved, offer infrequent IM injection versus frequent IV infusion, and lower costs.


Related Headlines